ReviewDoes influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research
Introduction
The possibility that influenza vaccines can attenuate the severity of influenza disease among those who become infected despite vaccination has been an intermittent topic of research and debate for decades [1]. Multiple animal and human virus challenge studies have demonstrated that influenza vaccines can reduce the signs and duration of influenza disease among those infected despite vaccination [e.g., [2], [3], [4], [5], [6], [7], but extrapolation from these studies is limited due to small sample sizes, use of challenge viruses that do not elicit severe disease, and lack of comparability between naïve animal models and the complex influenza exposure histories typical of people. Although attenuation of disease severity among vaccinees has been widely reported anecdotally, it has not been systematically or routinely evaluated. A major challenge lies in the heterogeneous and imprecise measurement of what constitutes severe influenza illness, with many indicators of disease severity based on types and levels of medical care rather than physiologic markers of disease severity. To our knowledge, there has been no review of published findings that report the frequency of influenza disease outcomes (e.g., hospital admission, ICU admission) among those who were vaccinated compared with those who were unvaccinated prior to their illnesses, leaving under-examined this potential protective benefit of vaccination.
We reviewed the literature for evidence to inform the question of whether influenza illness is less severe among individuals who received influenza vaccination compared with individuals with influenza illness who were unvaccinated prior to their illnesses. The primary objectives of the review are to (1) identify published articles that compare the occurrence of severe outcomes among influenza vaccinated versus unvaccinated individuals who have laboratory-confirmed influenza illness; (2) describe the features of these studies; (3) describe and summarize the findings of these studies and, if possible, calculate pooled estimate(s) for outcomes from studies with similar methodologies; (4) recommend methodological improvements that can be made to improve the ability to assess these proposed benefits of influenza vaccination.
Section snippets
Methods
We conducted a literature review to identify published findings comparing severity of influenza outcomes by vaccination status among individuals with laboratory-confirmed influenza virus infection. We began with a systematic review of the literature using key terms intended to identify reports of interest. We supplemented the systematic review with manual reviews of the literature based on consultation with colleagues and subject matter experts and with review of citations within the identified
Results
We identified 38 published articles reporting ≥ 1 association between influenza vaccination status and an indicator of the severity of influenza illness among individuals with laboratory-confirmed influenza [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46]. The systematic literature review, summarized in Supplemental Fig.
Discussion
In our narrative review of 38 publications that examined the association between influenza vaccination and the severity of laboratory-confirmed influenza disease, we identified multiple findings consistent with the argument that vaccination attenuates disease severity. Among five indicators of influenza disease severity that met criteria for calculating a combined effect, we found significantly reduced risk of three outcomes among vaccinated compared with unvaccinated individuals: Among eight
Declaration of Competing Interest
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Dr. Ferdinands reports non-financial support from Institute for Influenza Epidemiology (funded in part by Sanofi Pasteur), outside the submitted work. All other authors report no conflicts.].
Acknowledgments
The authors thank Palak Patel and Julie Mayo Lamberte for contributing to the review of articles. We also thank Manish Patel for feedback on an earlier draft of this manuscript.
References (63)
- et al.
Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice
Vaccine
(1993) - et al.
Mta-analysis in clinical trials
Control Clin Trials
(1986 Sep) - et al.
Vaccine-associated reduction in symptom severity among patients with influenza A/H3N2 disease
Vaccine
(2015 Dec 16) - et al.
Unexpected severity of cases of influenza B infection in patients that required hospitalization during the first postpandemic wave
J Infect
(2012 Nov) - et al.
Efficacy of inactivated trivalent influenza vaccine in alleviating the febrile illness of culture-confirmed influenza in children in the 2000–2001 influenza season
Vaccine
(2006 Apr 24) - et al.
Influenza vaccination and risk of hospitalization among adults with laboratory confirmed influenza illness
Vaccine
(2014 Jan 16) - et al.
Protection of trivalent inactivated influenza vaccine against hospitalizations among pandemic influenza A (H1N1) cases in Argentina
Vaccine
(2010 Jul 19) - et al.
Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza pneumonia among adults aged ≥65 years in Japan
Vaccine
(2018 May 17) - et al.
SHIVERS investigation team. Influenza vaccine effectiveness in preventing influenza-associated intensive care admissions and attenuating severe disease among adults in New Zealand 2012–2015
Vaccine
(2018 Sep 18) - et al.
Severity of mumps disease is related to MMR vaccination status and viral shedding
Vaccine
(2016 Apr 7)
Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies
Lancet Infect Dis
Artificially induced Asian influenza in vaccinated and unvaccinated volunteers
J Am Med Assoc
Induction of partial immunity to influenza by a neuraminidase-specific vaccine
J Infect Dis
Repeated vaccination against matched H3N2 influenza virus gives less protection than single vaccination in ferrets
npj Vaccines
Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans
Nat Med
Outcome of influenza infection: effect of site of initial infection and heterotypic immunity
Infect Immun
Hospitalization following outpatient medical care for influenza: US influenza vaccine effectiveness network, 2011–12-2015-16
Influenza Other Respir Viruses
Does influenza vaccination modify influenza severity? Data on older adults hospitalized with influenza during the 2012–2013 season in the United States
J Infect Dis
Influenza vaccination modifies disease severity among community-dwelling adults hospitalized with influenza
Clin Infect Dis
Paediatric Active Enhanced Disease Surveillance (PAEDS); Influenza Complications Alert Network (FluCAN) Collaboration. Influenza epidemiology, vaccine coverage and vaccine effectiveness in children admitted to sentinel Australian hospitals in 2017: Results from the PAEDS-FluCAN Collaboration
Clin Infect Dis
Project Pi12/2079 Working Group. Effect of influenza vaccination on the prognosis of hospitalized influenza patients
Expert Rev Vaccines
Project PI12/02079 Working Group. Repeated influenza vaccination for preventing severe and fatal influenza infection in older adults: a multicentre case-control study
CMAJ
CIBERESP Cases and Controls in Influenza Working Group Spain. Influenza vaccine effectiveness in preventing outpatient, inpatient, and severe cases of laboratory-confirmed influenza
Clin Infect Dis
High intensive care unit admission rate for 2013–2014 influenza is associated with a low rate of vaccination
Am J Respir Crit Care Med
Clinical presentation of influenza in children 6 to 35 months of age: Findings From a randomized clinical trial of inactivated quadrivalent influenza vaccine
Pediatr Infect Dis J.
CIBERESP Cases and Controls in Pandemic Influenza Working Group. Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors
J Antimicrob Chemother
Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City
BMJ
CIBERESP Cases and Controls in Pandemic Influenza Working Group, Spain. Predictive factors of severe multilobar pneumonia and shock in patients with influenza
Emerg Med J
Risk factors for hospitalization and severe outcomes of 2009 pandemic H1N1 influenza in Quebec
Canada Influenza Other Respir Viruses
Cited by (53)
Severity of influenza illness by seasonal influenza vaccination status among hospitalised patients in four South American countries, 2013–19: a surveillance-based cohort study
2023, The Lancet Infectious DiseasesCitation Excerpt :Growing evidence suggests that even in cases of breakthrough influenza virus infection, vaccination could confer health benefits. Several surveillance-based studies have reported reduced severity of influenza illness among hospitalised vaccinees, including lower odds of intensive care unit (ICU) admission, shorter length of stay in ICU, and shorter overall length of stay in hospital.7–12 For example, a recent US study of 8354 older adults hospitalised with influenza showed a 52–79% reduction in the odds of in-hospital death, a 37% reduction in the odds of ICU admission, and a shorter length of stay in hospital associated with influenza vaccination.13
- 1
MGT and JMF contributed equally.